Irina Tcherepanova

Irina Tcherepanova, Ph.D. is an independent consultant. Previously, she served as Chief Operating Officer at CoImmune Inc., providing leadership in guiding regulatory strategies and with an expertise in navigating complex regulatory landscapes for emerging therapies.

Her expertise lies in the areas of mRNA- and DNA-based drug substances, monoclonal antibodies, and recombinant protein drugs. Dr. Tcherepanova also has experience in cellular therapies including dendritic cell vaccines and cell and gene therapies for the treatment of immune disorders and cancer. Dr. Tcherepanova has a proven track record of achieving significant milestones, such as launching and supporting clinical trials as well as operational support for clinical drug products manufactured at an in-house cGMP facility.

Dr. Tcherepanova contributions to novel therapies development, technology transfer supporting in-licensed and out-licensed agreements, and clinical operations underscore her commitment to advancing biotechnology and increase patient’s access to the novel therapies. She is an accomplished author of over 30 publications, >80 presentation at national and international conferences, and is regularly invited to review scientific manuscripts for international per reviewed journals, as well an holder of several patents for inventions.

Dr. Tcherepanova received her Ph.D in Molecular Pharmacology from the Albert Einstein College of Medicine, followed by a post-doctoral fellowship in the Department of Pharmacology and Cancer Biology at the Duke University Medical Center.